349 related articles for article (PubMed ID: 26787895)
1. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.
Mehine M; Kaasinen E; Heinonen HR; Mäkinen N; Kämpjärvi K; Sarvilinna N; Aavikko M; Vähärautio A; Pasanen A; Bützow R; Heikinheimo O; Sjöberg J; Pitkänen E; Vahteristo P; Aaltonen LA
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1315-20. PubMed ID: 26787895
[TBL] [Abstract][Full Text] [Related]
2. 3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1.
Jokinen V; Mehine M; Reinikka S; Khamaiseh S; Ahvenainen T; Äyräväinen A; Härkki P; Bützow R; Pasanen A; Vahteristo P
Genes Chromosomes Cancer; 2023 Jan; 62(1):27-38. PubMed ID: 35822448
[TBL] [Abstract][Full Text] [Related]
3. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
4. Systematic molecular and clinical analysis of uterine leiomyomas from fertile-aged women undergoing myomectomy.
Äyräväinen A; Pasanen A; Ahvenainen T; Heikkinen T; Pakarinen P; Härkki P; Vahteristo P
Hum Reprod; 2020 Oct; 35(10):2237-2244. PubMed ID: 32829387
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs involved in the HMGA2 deregulation and its co-occurrence with MED12 mutation in uterine leiomyoma.
Mello JBH; Barros-Filho MC; Abreu FB; Cirilo PDR; Domingues MAC; Pontes A; Rogatto SR
Mol Hum Reprod; 2018 Nov; 24(11):556-563. PubMed ID: 30376129
[TBL] [Abstract][Full Text] [Related]
6. Genomics of uterine leiomyomas: insights from high-throughput sequencing.
Mehine M; Mäkinen N; Heinonen HR; Aaltonen LA; Vahteristo P
Fertil Steril; 2014 Sep; 102(3):621-9. PubMed ID: 25106763
[TBL] [Abstract][Full Text] [Related]
7. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
8. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.
Xie J; Ubango J; Ban Y; Chakravarti D; Kim JJ; Wei JJ
Genes Chromosomes Cancer; 2018 Oct; 57(10):485-494. PubMed ID: 29790226
[TBL] [Abstract][Full Text] [Related]
10. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
11. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
13.
Heikkinen T; Äyräväinen A; Hänninen J; Ahvenainen T; Bützow R; Pasanen A; Vahteristo P
Hum Reprod Open; 2018; 2018(4):hoy020. PubMed ID: 30895261
[TBL] [Abstract][Full Text] [Related]
14. Characterization of uterine leiomyomas by whole-genome sequencing.
Mehine M; Kaasinen E; Mäkinen N; Katainen R; Kämpjärvi K; Pitkänen E; Heinonen HR; Bützow R; Kilpivaara O; Kuosmanen A; Ristolainen H; Gentile M; Sjöberg J; Vahteristo P; Aaltonen LA
N Engl J Med; 2013 Jul; 369(1):43-53. PubMed ID: 23738515
[TBL] [Abstract][Full Text] [Related]
15. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
17. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
18. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
19. Global metabolomic profiling of uterine leiomyomas.
Heinonen HR; Mehine M; Mäkinen N; Pasanen A; Pitkänen E; Karhu A; Sarvilinna NS; Sjöberg J; Heikinheimo O; Bützow R; Aaltonen LA; Kaasinen E
Br J Cancer; 2017 Dec; 117(12):1855-1864. PubMed ID: 29073636
[TBL] [Abstract][Full Text] [Related]
20. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
